For instance, specific BRAF alterations (mutations and fusions) in pediatric-type gliomas and neurotrophic receptor tyrosine kinase (NTRK) family alterations in infant-type hemispheric gliomas can be targeted with molecularly tailored therapies. Here, BRAF is linked to glioma.